Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1587, Issue 2-3, 2002, Pages 164-173

  Banerjee, Debabrata ^a   Mayer Kuckuk, Philipp ^a   Capiaux, Gina ^a,b   Budak Alpdogan, Tulin ^a   Gorlick, Richard ^a   Bertino, Joseph R ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antifolate; Drug resistance; Fluoropyrimidine; In vivo imaging; Myeloprotection

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLOHEXIMIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DIHYDROFOLATE REDUCTASE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GANCICLOVIR; MESSENGER RNA; METHOTREXATE; OROTIC ACID DERIVATIVE; OROTIC ACID PHOSPHORIBOSYLTRANSFERASE; PHOSPHOTRANSFERASE; PROTEIN BAX; PROTEIN P14; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F; TRIMETREXATE; UNCLASSIFIED DRUG; URIDINE CYTIDINE MONOPHOSPHATE KINASE;

AUTOREGULATION; BONE MARROW CELL; COLORECTAL CANCER; DRUG SENSITIVITY; DRUG TRANSPORT; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; LEUKEMIA; LIVER METASTASIS; LUNG METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL CYCLE PROTEINS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; ENZYME INHIBITORS; FLUOROURACIL; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; NEOPLASMS; NUCLEOSIDE-PHOSPHATE KINASE; OXIDOREDUCTASES; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTORS;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0037130286     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(02)00079-0     Document Type: Review

References (89)

1. Karnofsky Memorial Lecture: Ode to methotrexate
2. Dihydrofolate reductase in folates and pterins
3. The cellular pharmacology of methotrexate
4. Enzymatic synthesis of folylpolyglutamates: Characterization of the reaction and its products
5. Methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood ALL: A pilot prognostic factor analysis
6. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates
7. Inhibition of phosphoribosyl-aminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamate
8. The pharmacology and clinical use of methotrexate
9. Gamma-glutamyl hydrolase (conjugase) purification and properties of the bovine hepatic enzyme
10. Isolation and characterization of pteroylglutamate hydrolase from rat intestinal mucosa
11. Pteroylglutamate hydrolase from human jejunal brush borders: Purification and characterization
12. Intracellular pteroylglutamate hydrolase from human jejunal mucosa: Isolation and characterization
13. Dihydrofolate reductase as a therapeutic target
14. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute leukemia
15. Characterization of transport mediated methotrexate resistance in human tumor cells with antibodies to the membrane carrier for methotrexate and tetrahydrofolate cofactors
16. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia
17. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake
18. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells
19. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake
20. A major superfamily of transmembrane facilitators that catalyze uniport, symport and antiport
21. Mutations/polymorphisms in the reduced folate carrier(RFC) are observed frequently in osteosarcoma tumor samples
22. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease
23. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia
24. Blast cell methotrexate polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia
25. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia
26. Acute monocytic leukemia: A myeloid subset that may be sensitive to methotrexate
27. The role of folylpolyglutamate synthetase and gamma-glutamylhydrolase in altering cellular folyl- and antifolyl-polyglutamates
28. Expression cloning of a human cDNA encoding folylpoly(-glutamate) synthetase and determination of its primary structure
29. Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: Marked variation of expression among leukemia patients
30. Hydrolytic cleavage of methotrexate-polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse
31. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity
32. Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance
33. Resistance to methotrexate due to gene amplification in a patient with acute leukemia
34. Gene amplification in a leukemia patient treated with methotrexate
35. Cytologic evidence for gene amplification in methotrexate resistant cells obtained from a patient with ovarian adenocarcinoma
36. Unstable methotrexate resistance in human small cell lung cancer associated with double minute chromosomes
37. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations
38. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53
39. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
40. Isolation and expression of an altered dihydrofolate reductase cDNA
41. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts
42. Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with a decreased binding to MTX in a human colon carcinoma cell line, HCT-8R4 resistant to this drug
43. Phenotypic expression in Escherichia coli and sequence of two Chinese hamster lung cDNA encoding different dihydrofolate reductase
44. Identification and characterization of a mutation in the dihydrofolate reductase gene from methotrexate resistant CHO cell line Pro-3 MTX RIII
45. Isolation and characterization of a variant dihydrofolate reductase cDNA from the methotrexate resistant murine L5178Y cells
46. Mutations in the gene for human dihydrofolate reductase: An unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate
47. The dihydrofolate reductase-thymidylate synthase gene in the drug resistance of malaria parasites
48. The induction of dihydrofolate reductase in leukocytes and erythrocytes of patients treated with methotrexate
49. Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate
50. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate
51. Translational regulation of the synthesis of dihydrofolate reductase
52. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region
53. E2F; A link between the Rb tumor suppressor protein and viral oncoproteins
54. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines
55. Effect of cyclin D1 over expression on drug sensitivity in a human fibrosacoma cell line
56. Thymidylate synthase m RNA level in adenocarcinoma of the stomach: A predictor of primary tumor response and overall survival
57. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal response and resistance to protracted infusion of fluorouracil and weekly leucovorin
58. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
59. P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
60. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
61. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma
62. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
63. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the sites of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil
64. Identification of an RNA binding site for human thymidylate synthase
65. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation
66. Human thymidylate synthase gene polymorphism determines response to 5-FU
67. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase
68. Isolation and characterization of Thymitaq (AG 337) and 5-Fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT-1080 cells
69. Random sequence mutagenesis and resistance to 5-fluoruridine in human thymidylate synthases
70. The regulation of E2F by pRB-family proteins
71. The E2F transcription factors: Key regulators of cell proliferation
72. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1S-regulatory genes
73. Role of E2F-1 in chemosensitivity
74. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer
75. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines
76. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT 8) sublines following exposure to two different clinically relevant dose schedules
77. Biochemical characterization of fluoropyrimidine resistant murine leukemic cell lines
78. High basal level gene expression of thymidine phosphorylase (platelet derived endothelial growth factor) in colorectal tumors is associated with non-response to 5 fluorouracil
79. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy
80. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5 fluorouracil in murine hematopoietic progenitor cells and human CD34+ enriched peripheral blood progenitor cells
81. Selective treatment of SCID mice bearing methotrexate transport resistant human ALL tumors with trimetrexate and leucovorin
82. Development of a retroviral construct containing a human mutated dhfr cDNA for hematopoietic stem cell transduction
83. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA
84. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer
85. Active site directed double mutants of dihydrofolate reductase
86. Gene therapy utilizing drug resistance genes: A review
87. Expression of a novel double mutant dihydrofolate reductase cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside
88. Generation of dual resistance to 4 hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene
89. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: A method to modulate gene expression